Prevalence and early outcome of bronchiectasis as an atypical presentation in COVID-19 patients

Abstract Introduction Bronchiectasis was considered as an uncommon radiological feature of corona virus disease 2019 (COVID-19) infection. The clinical course and outcome COVID-19 bronchiectasis overlap is still a point for research. aim this study to evaluate the prevalence, course, atypical presentation Methods A cross-sectional has been conducted from July 2021 February 2022 included 425 swab-positive patients who were examined by high resolution computed tomography chest during acute phase (4 weeks) Results Fourteen (3.3%) newly developed bronchiectasis-de novo. Patients with de novo had significantly higher cough score, frequency colored sputum mMRC respiratory distress ( p < 0.001) failure = 0.02) than no bronchiectasis. They also ICU’s admission 0.02), need non-invasive 0.01), invasive mechanical ventilation 0.001), duration ventilation, stay overall hospital 0.001). As outcome, death rate statistically among those De without 0.04). Conclusion patients. However, increases burden in It may have negative impact on outcome. Trial registration ClinicalTrials.gov . NCT04910113 Registered June 2, 2021.